| Market Capitalization (Millions $) |
533 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
231 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-115 |
| Cash Flow (TTM) (Millions $) |
77 |
| Capital Exp. (TTM) (Millions $) |
7 |
Business Description
Capricor Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Los Angeles, California, founded in 200 Capricor Therapeutics is focused on the development of innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's core technology is based on the mesenchymal stem cells (MSCs).
Capricor Therapeutics has developed a proprietary platform for the isolation, manufacturing, and delivery of MSCs. These cells are derived from the bone marrow, fat tissue, or placenta of healthy donors. The platform also includes a process for culturing MSCs that is designed to maximize their therapeutic potential.
Capricor Therapeutics is currently conducting clinical trials of its lead product candidate, CAP-1002, which is an allogeneic cell therapy consisting of MSCs. CAP-1002 is being evaluated in multiple indications, including Duchenne muscular dystrophy (DMD), cardiac diseases, and pulmonary arterial hypertension. The company has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for CAP-1002 in DMD.
Capricor Therapeutics also has a range of preclinical programs focused on the discovery and development of new cell-based therapies for the treatment of other diseases, including neurological disorders.
In addition to its own research and development efforts, Capricor Therapeutics has collaborations with several academic institutions and industry partners. The company is financially supported by a combination of government grants, private investors, and partnerships.
Overall, Capricor Therapeutics is a biotechnology company that is focused on developing innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's MSC-based platform technology has the potential to address significant unmet medical needs, and it is currently being evaluated in multiple clinical trials.
Company Address: 10865 Road to the Cure, Suite 150 San Diego 92121 CA
Company Phone Number: 727-1755 Stock Exchange / Ticker: NASDAQ CAPR
|
6.13%